Abstract Results from multinational clinical trials are globally adopted into the routine clinical practice in most countries. Changes in the natural history and incidence of certain diseases as well as in drugs toxicities related to yearly seasons have been reported, however, variations related to climate have never been described. In our study, we assessed whether yearly seasons and climate could influence the chemotherapy toxicity profile. We analyzed the toxicities recorded in the phase III GEICAM 9906 study which was run in different geographically and climatically/seasonally regions in Spain. In this trial 1246 patients were randomized and eligible to receive FEC90 96 cycles or FEC90 94 cycles followed by eight doses of weekly paclitaxel (T). The results showed differences in hematological and non-hematological toxicities in relation to the season of the year and the climate of the area in which the treatment was administered. We found a higher hematological toxicity in warm seasons (spring and summer) and in Oceanic climate regions (Neutropenia G4: 7.8 vs. 1.0 vs.
Introduction
Chemotherapy is an integral part in the therapeutic management of the majority of tumor types. Efficacy and safety are assessed in clinical trials which are often conducted in several countries. The communication and diffusion of the results are globalized, as are the therapeutic attitudes and treatment regimens. However, there are variables in different countries and geographical areas which can have an influence on trial outcomes and, as such, need to be taken into account in the data analyses. One of these variables is climate.
Variations in the incidence of diseases related to the yearly seasonal stages have been published [1] . These include the incidence of cardiovascular [2] and cerebrovascular disease with a peak incidence during the winter [3, 4] and infectious disease [5] . In oncology, there have been reports of seasonal differences in lymphoma [6] , breast cancer [7, 8] , and other tumor types [9] .
Relationships between the season of the year and the natural history of the disease have been also published. A Norwegian prostate cancer study showed better prognosis in patients who were diagnosed during the summer and the autumn [10] . Also in Norwegian patients, there were differences in lung cancer incidence; the authors postulated that the underlying cause of this prognostic variation was the physiological modifications produced as a result of the differences in the levels of exposure to vitamin D [11, 12] .
Similarly, there have been descriptions of seasonal changes in the activity of some enzymatic systems responsible for the metabolism of substances and toxins, which can result in toxicity variations to specific drugs. As an example, the hepatic toxicity induced by tetracyclines in an animal model was greater in winter and autumn due to a decrease in the levels of toxin conjugation and excretion by the liver [13] . Also described in another murine model was the circadian and seasonal variation in the nephrotoxicity induced by amikacin and gentamicin, and the haematological toxicity induced by adriamycin and epirubicin [14] [15] [16] [17] .
Experimental carcinogenesis studies performed in animals showed that the success in the tumors induction varied as a function of the season of the year. For example, 56 and 61% of Sprague-Dawley rats developed breast cancer when exposed to DMBA in the spring and summer, while only 24% develop the tumors if induced in the autumn [18] .
Cytostatic drugs used in the treatment of cancer are characterized by narrow therapeutic margins. Slight modifications can have an impact on the toxicity profile and, as such, could affect the conditions of the drugs' employment. Up to date, there have not been any publications addressing the influence of climate on chemotherapy toxicity.
Patients and methods
We analyzed the toxicities recorded in the GEICAM 9906 study [19] . This trial included 1,246 patients recruited in 65 Spanish hospitals. Patients were randomized to receive FEC90 (5-fluorouracil 600 mg/m 2 , epirubicin 90 mg/m 2 , and cyclophosphamide 600 mg/m 2 ) for six cycles every 21 days; or sequential FEC90 for four cycles every 21 days followed by weekly paclitaxel (100 mg/m 2 ) for 8 weeks. 10.780 cycles were administered, 6.191 of FEC90 and 4,589 of paclitaxel.
The hematological and non-hematological toxicities were assessed in relation to climate (seasonal) and geographical areas. The seasons were defined as: spring (from 21st March to 21st June), summer (from 22nd June to 23rd September), autumn (from 24th September to 21st December), and winter (from 22nd December to 20th March). The geography-affected climate areas were defined according to the information provided in the Spanish Education Ministry web page [20] . They were classified as: Oceanic (characterized by mild temperatures throughout the year (10-20°C) and corresponding to the regions of Galicia, Cantabria and Basque Country); Mediterranean (characterized as high temperatures in summer and mild in winter and corresponding to the Regions of Catalunya, Balearic Islands, Valencia, Murcia, Andalucia including Almeria, Malaga, Sevilla, Huelva, and Cadiz); Continental (characterized by extremes temperatures, and corresponding to the regions of Castilla la Mancha, Aragon, Navarra, Extremadura, Castilla-Leon, and Andalucia including Granada, Cordoba, and Jaen) and Sub-tropical (characterized by temperatures between 18 and 25°C throughout the year, and corresponding to the Canary Islands). This last geographic area was excluded from the current analyses because the original study had very few patients recruited from there.
Recorded toxicities were segregated according to the different seasons and Geographic-climatic areas. Contingency tables were used to compare the toxicity versus the season as well as the toxicity versus the climate area in a separate analysis. The v 2 test was used to check the hypothesis that the two variables were independent in each analysis separately. Statistical significance was set at P \ 0.05.
Results
We analyzed all toxicities by grade for both treatment arms and distributed them by the seasons of the year (Table 1) and by Geographic-climate areas (Table 2) . Toxicity items and grades were different between the regimens and the tables because only the statistically significant differences in toxicities were included.
In general, the statistically significant differences observed were only in low grade toxicities (except for neutropenia and vomiting).
The results showed statistically significant differences for some of the toxicities related to the season of the year and the Geographic-climate area where the patients were treated. We observed a higher hematological toxicity with both FEC90 and paclitaxel in warm seasons (spring and summer) and in Oceanic climate regions. Asthenia was a symptom that occurred with greater frequency in the summer period, as well as in the Mediterranean areas. Liver transaminase elevations were more frequent in the summer and in the Oceanic areas. Myalgias and secondary sensory neuropathy to paclitaxel were recorded more frequently during autumn.
Commentary
Internationalization of clinical research has resulted in globalization of therapeutic approaches and regimens. Changes in the incidence and intensity of toxicities to several drugs in relation with the yearly seasons have been reported in animal models. However, seasonal and climate differences in chemotherapy toxicity in patients have not been described yet.
We have seen that the tolerability of a specific drug or treatment regimen could be affected by the yearly seasons and the climate conditions in which the treatment is administered. Differences in toxicity can lead to differences in dose reductions. Bonadonna et al. [21] showed a dose-response effect to chemotherapy when administered in the adjuvant setting to patients with breast cancer. When CMF was administered at full or almost full doses (greater than or equal to 85%) patients had a 5-year disease free survival of 77%, in contrast, only 67% of patients were disease free at 5 year when only 65% of the planned doses were administered. Based on the results observed in this work, and knowing the slim therapeutic margin of chemotherapy, drug efficacy could potentially be affected by climatic conditions. Due to that, the toxicity analysis as a function of climate variables should be taken into account when data from clinical trials are reviewed. 
